Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Nasal Antihistamines Market to top US$ 1.9 Bn in 2021 Steered by Surging Demand for Nasal Sprays: FMI

This image opens in the lightbox

News provided by

Future Market Insights

19 Oct, 2021, 14:00 GMT

Share this article

Share toX

Share this article

Share toX

A latest study published by Future Market Insights (FMI) uncovers factors propelling the demand in the nasal antihistamines market. It offers analysis of scope for expansion in various segments including product, age group, distribution channel, and region.

DUBAI, UAE, Oct. 19, 2021 /PRNewswire/ -- As per a recent survey by FMI, the global Nasal Antihistamines Market is projected to total US$ 1.9 billion in 2021. Rising preference for alternative modes of drug administration other than injectable and oral is propelling the demand for the nasal drug delivery solutions. Driven by this, the market is expected to reach US$ 3.08 billion by the end of 2031.

A significant rise in prevalence of allergies has been witnessed across the world due to the increasing sensitization to allergens and intensifying air pollution. According to the Asthma and Allergy Foundation of America, allergies are the sixth leading cause of chronic illness in the U.S. The country reports over 50 million cases of allergies every year. Increasing demand for speedy relief from allergic reactions such as nose congestion, itchy and runny nose, and sneezing is creating immense sales opportunities for the market.

Several players in the market are focusing on launching novel products to capitalize on this opportunity. For instance, Glenmark Pharma announced launching a new nasal spray named Ryaltris in India in May 2021. In response to a slew of novel product launches, sales are expected to rise at a CAGR of 4.6% during the forecast period 2021-2031.

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-13708

As per FMI, nasal sprays are the most preferred product available in the nasal antihistamines market, accounting for around 90% of global sales. Attributes such as fast relief, easy to carry, and cost-effectiveness are accelerating the demand for nasal sprays.

"Growing inclination towards the non-invasive treatments and increasing approvals by the Food and Drug Administration (FDA) for over-the-counter (OTC) sales of prescription-based nasal antihistamines are expected to favor the market growth in the coming years," says the FMI analyst.

Key Takeaways from Nasal Antihistamines Market Study

  • The U.S. is expected to hold the largest revenue share in the North America market, accounting for 90.7% of sales in the region in 2021.
  • The U.K. is projected to emerge as a highly remunerative market, contributing more than 17.9% of sales in Europe in 2021.
  • The market in China is forecast to witness the fastest growth in East Asia, expanding at a CAGR of 6.5% over the assessment period.
  • Sales of nasal antihistamines in South Korea and Japan are anticipated to rise at 3.8% and 5.3% CAGR, respectively, by the end of the coming decade.
  • Based on distribution channel, retail pharmacies are estimated to account for over 40% of revenue share in the segment, projecting sales growth at a CAGR of 4.4% through 2031.

Key Drivers

  • Increasing healthcare expenditure, ease in product approvals, and rising funding for life science research, and new product launches are expected to accelerate the growth of the nasal antihistamine market.
  • Rising prevalence of respiratory diseases including asthma, allergic rhinitis, and others are fuelling the demand for low-cost generic medical products across China, India, Mexico, Brazil, and South Africa, which is propelling the demand for nasal antihistamines.

Key Restraints

  • Side effects associated with nasal antihistamines such as dizziness, dry mouth, and nose, headache, and others is hampering sales of nasal antihistamines.
  • Availability of alternatives such as oral antihistamines and others are hindering the growth of nasal antihistamines market.

Discover more about the nasal antihistamines analysis with figures and data tables, along with the table of contents - https://www.futuremarketinsights.com/ask-question/rep-gb-13708

Competitive Landscape

As per FMI, the global market is dominated by Bayer Healthcare, Novartis AG, Glenmark Pharmaceuticals, GlaxoSmithKline, Cipla, Merck & Co., Sun Pharmaceuticals, Viatris, Proctor & Gamble, Ascend Laboratories, Centaur Pharmaceuticals, J pharmaceuticals, Sato Pharmaceuticals, and Altair Pharmaceuticals.

Leading players are emphasizing on launching new products and receiving regulatory approvals to expand their product portfolios. Some of the manufacturers are aiming at engaging into strategic collaborations, acquisitions, agreement, and merger to increase their market share and expand their global presence. For instance,

  • In April 2020, Cipla, an Indian multinational pharmaceutical company, announced receiving final approval for its generic version of Proventil® High Functioning Autism (HFA) Inhalation Aerosol, from the U.S. FDA. The product approval will assist the company to strengthen their presence in the U.S. pharmaceutical market.
  • In December 2020, GlaxoSmithKline, a leading pharmaceutical company in India, announced launching a saline wash natural nasal spray, Otrivin Breathe clean. It offers symptomatic relief from allergic rhinitis with moisturizing benefit as it has natural glycerin in it.

Some of the key players operating in the market profiled by FMI are:

  • Bayer Healthcare LLC
  • Novartis AG
  • Glenmark Pharmaceuticals
  • GlaxoSmithKline
  • Sun Pharmaceuticals
  • Cipla
  • Merck & Co.
  • Viatris (Meda Pharmaceuticals)
  • Proctor & Gamble
  • Ascend Laboratories LLC (Alkem Laboratories)
  • Centaur Pharmaceuticals
  • J Pharmaceuticals
  • Alitair Pharmaceuticals
  • Sato Pharmaceuticals

More Valuable Insights on Nasal Antihistamines Market

FMI, in its new report, offers an unbiased analysis of the global nasal antihistamines market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in nasal antihistamines market with detailed segmentation:

By Product:

  • Nasal Spray
  • Nasal Drops

By Age Group:

  • Adult
  • Pediatric

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

We Offer tailor-made Solutions to fit Your Requirements, Request Customization - https://www.futuremarketinsights.com/customization-available/rep-gb-13708 

 Key Questions Covered in the Report

  • The report offers insight into nasal antihistamines market demand outlook for the forecast period 2021-2031
  • The market study also highlights projected sales growth for nasal antihistamines market between 2021 and 2031
  • Nasal antihistamines market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
  • Nasal antihistamines market share analysis, covering key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others

FMI is hosting a talk show in collaboration with SPRING to uncover the paths of latest innovations in packaging. Join our Talk show "The Rise of Intelligent Packaging' by registering here: https://www.futuremarketinsights.com/event/the-rise-of-intelligent-packaging

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com  
Website: https://www.futuremarketinsights.com/ 
Report: https://www.futuremarketinsights.com/reports/nasal-antihistamines-market
Press Release Source: https://www.futuremarketinsights.com/press-release/nasal-antihistamines-market

Logo: https://mma.prnewswire.com/media/1197648/FMI_Logo.jpg

Modal title

Also from this source

Isoprene Rubber Latex Market is Projected to Expand at a CAGR of 8.1% between 2024 and 2034 | Future Market Insights, Inc.

Isoprene Rubber Latex Market is Projected to Expand at a CAGR of 8.1% between 2024 and 2034 | Future Market Insights, Inc.

The isoprene rubber latex industry is predicted to be valued at USD 922 million by 2024. The market valuation is estimated to be USD 2,005.3 million...

Growing Demand for Premium Distilled Agave-based Beverages to Propel Mezcal Market at a CAGR of 14.2% by 2034 | Future Market Insights, Inc.

Growing Demand for Premium Distilled Agave-based Beverages to Propel Mezcal Market at a CAGR of 14.2% by 2034 | Future Market Insights, Inc.

According to Future Market Insights (FMI), the global mezcal market demand is estimated to reach a valuation of USD 635 million by 2024. Over the...

More Releases From This Source

Explore

Pharmaceuticals

Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.